The 100% Pharma Tariff Starts Tomorrow - But Only for Annex III. Everyone Else Has 60 Days.
## The 100% Pharma Tariff Starts Tomorrow - But Only for Annex III. Everyone Else Has 60 Days.
At 12:01 a.m. on Friday, July 31, 2026, the Section 232 pharmaceutical tariff goes live - an additional duty of up to 100% on patented pharmaceutical articles, active pharmaceutical ingredients (APIs), and key starting materials.
It does not go live for everyone. The April 6, 2026 proclamation phased the action in two stages:
- July 31, 2026 - the duty applies to covered products of the companies named in Annex III of the proclamation.
- September 29, 2026 - the same duty applies to the same covered articles for every other company.
If you are not an Annex III company, tomorrow is not your deadline. September 29 is - and you have sixty days of runway that most of your competitors have not yet priced into their plans. What you do with those sixty days is the most consequential import decision in your calendar this year.
What Is Actually Covered
The scope is narrower than "pharmaceuticals" and wider than most importers assume. A product is covered if it is:
- A patented pharmaceutical article - subject to a valid, unexpired U.S. patent, and listed either in the FDA's Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book) or the FDA's Lists of Licensed Biological Products (the Purple Book); or
- An API or key starting material for such an article.
Annex I of the proclamation lists the covered products by HTSUS number. That annex, not your product description, is the operative document - if you are not sure how your line classifies, start with how to read an HTS code and then reconcile against Annex I with your broker.
What Is Not Covered
Four exclusions do real work here:
1. Generics. FDA-approved pharmaceutical articles and their ingredients that are not subject to a valid, unexpired U.S. patent and are off exclusivity are outside the action entirely. For most generic importers this tariff simply does not exist.
2. U.S.-origin pharmaceutical products. Origin, not shipping point.
3. Certain HTSUS codes listed in Annex IV.
4. Products of the 13 companies listed in Annex II that entered most-favored-nation pricing agreements with HHS - exempt from any additional Section 232 pharmaceutical duty until January 20, 2029.
The Rate Ladder Is Not 0 or 100
The headline number is 100%, but the operative rate for most covered lines is far lower. The proclamation sets a graduated structure:
- 0% - orphan drugs (all approved indications designated orphan under the Orphan Drug Act), nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, CBRN medical countermeasures, and other specialty products identified by the Secretary of Commerce.
- 10% - products of the United Kingdom.
- 15% - products of the European Union, Japan, South Korea, Switzerland, and Liechtenstein.
- 20% - products of companies with an onshore production plan approved by the Secretary of HHS, through April 30, 2030.
- 100% - everything else covered by Annex I.
Two consequences follow. First, country of origin is now worth more than it has ever been on a pharma entry - the spread between a Swiss-origin API at 15% and the same molecule of another origin at 100% is 85 points of entered value. Second, the 20% onshoring rate and the 0% specialty carve-outs mean the honest first step is a line-by-line eligibility screen, not a panic buy.
Also note this duty stacks. It sits on top of the base MFN rate and any other layer that already applies to the line. Run your actual entries through the tariff stacking calculator and the landed cost calculator before you commit to a purchase order - and read our stacking guide for how the layers compound.
Importers screening large SKU books line by line against Annex I and Annex IV frequently use classification and landed-cost software such as Zonos to model exposure before the broker files. (Disclosure: this is an affiliate link - FreightFigures may earn a commission if you sign up, at no additional cost to you. See our affiliate disclosure.)
The Sixty-Day Play - and Why Bonded Warehousing Is the Wrong Tool Here
We spend a lot of time on this site arguing that when a tariff regime is unstable, a customs bonded warehouse is the right answer, because duty is assessed at the withdrawal date rather than the arrival date. That logic is exactly backwards for this action, and it is worth being blunt about it.
The Section 232 pharmaceutical rate for non-Annex-III importers is scheduled to go up on September 29, from zero to as much as 100%. Withdrawal-date assessment means goods sitting in bond on September 29 withdraw at the *new* rate. Bonding covered pharma during this window does not defer the tariff - it guarantees you pay it.
The correct move for a non-Annex-III importer with covered product is the opposite of the bonded play:
- Land it and enter it for consumption before September 29. Consumption entry fixes duty liability at the rate in effect on the entry date. Cargo entered September 28 at 0% stays at 0% forever; the same cargo entered September 30 owes the full stack.
- Check your FTZ status rules before you use a zone. Recent tariff actions have required covered goods admitted to a foreign-trade zone to take privileged foreign status, which locks treatment at admission. Whether that helps or hurts you here depends entirely on your admission date - see FTZ vs bonded warehouse.
- Do not assume an in-transit grace window. The two July actions both offered transition relief keyed to entry, not loading, and both windows closed this week. Plan as though September 29 is a hard entry deadline, because it is drafted as one.
The Part Nobody Plans For: Where the Front-Loaded Inventory Goes
Every front-loading cycle ends the same way. Importers do the duty math correctly, pull purchase orders forward, and then discover in week six that they have bought four months of inventory and have nowhere to put it. We watched exactly this happen through June's front-loading surge ahead of the July deadlines, and warehouse space near the major gateways tightened well before the deadline itself.
If you are pulling volume forward ahead of September 29, solve the storage question in August, not in late September. Three specifics worth planning around:
- Duty-paid inventory needs ordinary warehousing, not bonded space. Once you have entered for consumption to lock the rate, the goods are in free circulation. What you need is conventional storage with capacity for a temporary four-to-six-month bulge - and pharma inventory typically needs controlled, secured, well-documented space with real lot-level traceability.
- Devanning and transload capacity is the actual bottleneck. Front-loading means containers arriving faster than your normal receiving cadence absorbs. Getting boxes stripped and returned quickly avoids demurrage and detention charges that can quietly exceed the duty you were trying to avoid.
- Do not let it become General Order cargo. Freight that sits unentered past the statutory window goes to a General Order warehouse, and getting it back is slower and more expensive than storing it properly in the first place. During a front-loading surge this happens more often, not less.
If your cargo comes through the Southeast, our Port of Charleston importer's guide covers local drayage, devanning, and storage economics, and the drayage cost breakdown will tell you what the moves should run.
The Compliance Work to Do in August
Regardless of which side of Annex III you are on, four tasks belong in the next thirty days:
1. Classify. Confirm the HTSUS classification of every pharmaceutical line you import and check it against Annex I and Annex IV. Misclassification here carries retroactive assessment risk on a duty this large.
2. Determine patent and exclusivity status. Orange Book and Purple Book listing plus a valid, unexpired patent is the trigger. Off-patent, off-exclusivity generics are out.
3. Document country of origin. Not country of export. The 10%, 15%, and 100% tiers turn entirely on this, and CBP is expected to scrutinize origin claims on pharmaceutical entries closely.
4. Screen for the 0% specialty carve-outs. Orphan designation, nuclear medicine, plasma-derived, fertility, cell and gene, antibody drug conjugates, and CBRN countermeasures all carry a zero rate. If any of your book qualifies, that is the cheapest exposure reduction available.
Bottom Line
Tomorrow's deadline belongs to a specific list of companies. The deadline that belongs to the rest of the pharmaceutical import market is September 29, 2026, and it is a consumption-entry deadline, not a loading deadline. The playbook is unusually clear for once: screen your lines against the annexes, confirm origin, take the 0/10/15/20 rates you are entitled to, enter what remains before the date - and have somewhere to put it when it lands.
Frequently Asked Questions
Common questions about the 100% pharma tariff starts tomorrow - but only for annex iii. everyone else has 60 days.
When does the 100% Section 232 pharmaceutical tariff take effect?
July 31, 2026 for covered products of the companies named in Annex III of the April 6, 2026 proclamation, and September 29, 2026 for the same covered articles imported by all other companies.
Which pharmaceutical products are covered?
Patented pharmaceutical articles subject to a valid, unexpired U.S. patent and listed in the FDA's Orange Book or Purple Book, plus the active pharmaceutical ingredients and key starting materials for those articles. Annex I of the proclamation lists the covered products by HTSUS number.
Are generic drugs subject to the pharmaceutical tariff?
No. FDA-approved pharmaceutical articles and their associated ingredients that are not subject to a valid, unexpired U.S. patent and are off exclusivity are not covered by the Section 232 action. U.S.-origin pharmaceutical products and certain HTSUS codes listed in Annex IV are also excluded.
Is the rate always 100%?
No. Products of the United Kingdom are dutiable at 10%; products of the EU, Japan, South Korea, Switzerland, and Liechtenstein at 15%; products of companies with an onshore production plan approved by the HHS Secretary at 20% until April 30, 2030. Orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, and CBRN medical countermeasures are at 0%. Products of the 13 Annex II companies with HHS most-favored-nation pricing agreements are exempt until January 20, 2029.
Should I put covered pharmaceuticals in a bonded warehouse before September 29?
Generally no, and this is the opposite of the usual advice. A bonded warehouse assesses duty at the rate in effect on the withdrawal date. Because this rate is scheduled to rise on September 29 rather than fall, goods held in bond across that date withdraw at the higher rate. To fix liability at the current rate, file a consumption entry before September 29.
What should I do with inventory I pull forward ahead of September 29?
Plan conventional (non-bonded) storage capacity in August, before the surge. Once you enter for consumption to lock the rate, the goods are in free circulation and need ordinary warehousing with lot-level traceability, plus devanning and transload capacity fast enough to keep containers moving and avoid demurrage and detention. Freight left unentered past the statutory window ends up as General Order cargo, which is slower and costlier to recover.
Related Tools
Need bonded storage near the Port of Charleston?
C&C Warehouse is a CBP-bonded & General Order facility minutes from the port — bonded storage & duty deferral, container devanning, transload/cross-dock, overweight reworking, and drayage coordination. Leave your email and the operator (not a call center) replies within one business day.
C&C Warehouse is operated by FreightFigures' publisher. candcwarehouse.com